For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.Lexicon Pharmaceuticals acknowledged the receipt of an FDA complete response letter for sotagliflozin (Zynquista, Lexicon) in a press release on Dec. 20. The company had filed a new
Despite a worldwide need for more corneal transplant tissue, few options exist beyond human donors.According to a study published in JAMA Ophthalmology, just one cornea…
A computerized clinical decision support tool implemented as a diagnostic stewardship intervention led to an approximate 50% decrease in urine culture testing for patients with…
At the American Diabetes Association (ADA), we are dedicated to advancing care that will improve the lives of everyone affected by diabetes—until the day we…
The Health Resources and Services Administration announced $60 million in funding to expand the hours of operation for 125 community health centers and improve access…
A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without diabetes, a systematic review published in Annals…
People who drink coffee in the morning have a lower risk for death from all causes compared with those who do not drink coffee at…
The FDA has proposed a rule requiring a new nutrition label on the front of most packaged foods, offering consumers easily visible information about the…
More women than ever have joined gastroenterology in the past 20 years — a staggering 219% increase according to the Association of American Medical Colleges…
The American College of Cardiology recently issued an expert consensus document outlining a novel staging system and decision pathway for the diagnosis, treatment and longitudinal…
COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.
